drugset / Trial / NCT06090721

DMT310-009 Topical in the Treatment of Acne Vulgaris

NCT06090721

Phase 3 Completed 520 enrolled Dermata Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris

Timeline

Start
2023-12-08
Primary completion
2025-03-31
Completion
2025-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject DMT310 Unknown Topical

Indications